This Stock is Revolutionizing Healthcare with Non-Invasive Cancer
Detection and FDA-Cleared Eye Care Products While Scaling Across the
U.S. Market! ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏



 

_You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS. If you no longer wish to receive
these partner emails, please unsubscribe
[[link removed]]
here. This message is from Small Caps Daily._

-------------------------

YD BIO LTD. (NASDAQ: YDES) [[link removed]]IS
REVOLUTIONIZING HEALTHCARE WITH NON-INVASIVE CANCER DETECTION AND
FDA-CLEARED EYE CARE PRODUCTS WHILE SCALING ACROSS THE U.S. MARKET!

[ydes2] [[link removed]]

YD BIO LTD. (NASDAQ: YDES) is not your typical biotech startup —
it’s a commercial-stage powerhouse delivering innovative solutions
in EARLY CANCER DETECTION AND OCULAR HEALTH. With FDA-cleared eye
care products already on the market and the OkaiDx™ blood-based
diagnostics platform expanding to_ pancreatic and colorectal cancer
detection_ in 44 U.S. states, YDES is actively transforming the
future of healthcare. Operating through a CAP-accredited,
CLIA-certified U.S. laboratory and supported by a nationwide
telehealth network, the company is making precision diagnostics more
accessible than ever. 

YDES’ strategic partnerships with EG Biomed and 3D Global Biotech
provide long-term access to cutting-edge diagnostics and regenerative
eye therapies, creating a diversified platform that spans multiple
high-growth markets.

By combining revenue-generating commercial operations with an
ambitious pipeline in regenerative medicine, YDES is positioned for
scalable impact in global healthcare. From early cancer detection to
advanced ocular therapies, the company is turning scientific
innovation into real-world solutions for patients and providers
alike. 

YDES is one of the few biotech companies that’s already moving from
lab innovation to market execution. With a U.S. expansion underway,
OkaiDx™ testing in 44 states, FDA-cleared eye care products, and a
strong patent portfolio, YDES is positioned to scale rapidly in
2026. Investors and healthcare leaders should watch closely as YD Bio
turns cutting-edge science into tangible patient solutions.

LEARN HOW YDES IS TURNING GROUNDBREAKING SCIENCE INTO REAL-WORLD
HEALTHCARE SOLUTIONS. [[link removed]]

We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of YD Bio Ltd. (NASDAQ: YDES). The compensation consists of up to
$6,500 and was received/will be received from Interactive Offers.

This communication should not be considered as an endorsement of the
securities of adviser YD Bio Ltd. (NASDAQ: YDES) and we are not
responsible for any errors or omissions in any information provided
about the securities of YD Bio Ltd. (NASDAQ: YDES) or Interactive
Offers.

We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.

This disclosure is made as of 1/7/2026.

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]

Behind the Markets
[[link removed]]

_You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these partner emails, please unsubscribe here
[[link removed]]._

TODAY'S BONUS CONTENT: Wall Street doesn't want you to know about
these 3 AI stocks
[[link removed]]

 _(By clicking this link you agree to receive emails from Trading
Tips and our affiliates. You can opt out at any time. -__ __Privacy
Policy)_ [[link removed]]